Developer docs
API playgroundTry for free, no card

Search company profiles

Mass General Brigham Ventures

Full company profile

uuid0002so7

Namestring
Mass General Brigham Ventures
Legal namestring
Mass General Brigham Incorporated
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Mass General Brigham Ventures is the strategic venture capital arm of Mass General Brigham Incorporated, a non-profit integrated healthcare system headquartered in Boston, Massachusetts. Founded in 2008 and operating with 11–50 employees from offices in Boston, Cambridge, Salem, and Somerville, the venture unit invests in early-stage healthcare companies whose technologies align with the parent system's clinical and research priorities. Its disclosed portfolio spans pediatric mental health (InStride Health), virtual dementia care (Rippl, subsequently acquired by Harbor Health), AI-powered clinical data abstraction (Carta Healthcare), respiratory therapeutics (Nocion Therapeutics), and preclinical neurodegenerative-disease biotechnology (Violet Therapeutics), with check sizes consistently sized as minority participation rather than lead positions.

The venture unit's investment activity between October 2024 and June 2026 — five rounds across seed, Series A, Series B extension, and Series C totaling over $168 million in combined round size — demonstrates programmatic co-investment alongside ARCH Venture Partners, General Catalyst, GV, F-Prime, UPMC Enterprises, Kin Ventures, and other healthcare-focused funds. The underlying competitive advantage is structural rather than financial: portfolio companies gain potential access to Mass General Brigham's five nationally recognized hospitals, 2.5 million annual patients, nearly $2 billion in annual research funding, and over 3,700 ongoing clinical trials, alongside the parent system's dedicated Artificial Intelligence and Gene and Cell Therapy research institutes.

As a non-profit strategic CVC, Mass General Brigham Ventures is funded by the parent system rather than external LPs, does not disclose revenue or AUM, and participates in rounds as a strategic/clinical-alignment investor. Its business model centers on deal sourcing from the parent system's clinical and research pipeline, portfolio diversification across therapeutic areas and stages, and downstream commercial validation through MGB's integrated care delivery network rather than on management fees or fund performance metrics typical of for-profit VCs.

Short descriptiontext

Mass General Brigham Ventures is the strategic venture capital arm of Mass General Brigham, investing as a participating investor in early-stage healthcare companies across digital health, AI, and biotech that align with the parent system's clinical and research priorities.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSomerville, United States
HQ citystring
Somerville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare venture capital, early-stage healthcare investing, biotech venture funding, medical innovation investing, strategic healthcare investments
Industry4 codes
PRIMARYFSANAHAF
Corporate Strategic Partnership & Ecosystem Investment Arms
SECONDARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
SECONDARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANAAAC
Late-Stage Venture Capital (Series C+)
NAICS code2 codes
  • Other Financial Vehicles52599
  • Other Investment Pools and Funds5259
SIC code1 code
  • Investment Advice6282
Product category
Healthcare Venture Capital
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Operations, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 5 records shown
1Mass General Brigham Health Plan
Description

Health insurance plan offered by the Mass General Brigham system

massgeneralbrigham.org
+4 more records
Core offering1 text field

Mass General Brigham Ventures is the venture capital arm of Mass General Brigham, providing strategic equity investments in early-stage healthcare companies. It deploys capital across seed, Series A, Series B, and Series C rounds into startups operating in pediatric mental health, neurodegenerative disease biotechnology, dementia care, clinical data abstraction, and chronic cough therapeutics aligned with the parent system's clinical and research priorities.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Mass General Brigham Ventures operates as the venture capital investment arm of Mass General Brigham, an integrated healthcare system. The entity invests in healthcare innovation companies across various stages and therapeutic areas, including pediatric mental health (InStride Health), neurodegenerative disease biotechnology (Violet Therapeutics), dementia care (Rippl), and clinical data management (Carta Healthcare). The investment portfolio spans from seed to Series C funding rounds.

Product and service1 record
1Venture Capital Investment Services
CategoryHealthcare Venture Capital
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-10
Description

Dana-Farber Cancer Institute and Mass General Brigham agreed to collaborate on physician assistants following what was described as a 'breakup' between the two Boston hospital systems. The physician assistants are employed by Dana-Farber but contracted to work in Brigham's inpatient oncology units, representing a collaborative employment arrangement.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Amed Ventures
TypeDirect peer
Description

A CVC platform representing a consortium of non-profit health systems investing jointly in healthcare startups. Highly comparable as a multi-system healthcare CVC with overlapping strategic thesis and similar fund mechanics.

TypeBroad incumbent
Description

The venture arm of UnitedHealth Group's Optum, the largest healthcare services and innovation platform in the U.S. Comparable as a healthcare-focused CVC, but with substantially larger scale and broader strategic remit than MGB Ventures.

TypeDirect peer
Description

The venture and innovation arm of UPMC, a large integrated payer-provider system. Directly comparable as a hospital-system CVC; notably co-invested with Mass General Brigham Ventures in Carta Healthcare's Series B1, evidencing direct overlap in deal-making.

TypeDirect peer
Description

The venture capital arm of Kaiser Permanente, one of the largest U.S. integrated non-profit healthcare systems. Directly comparable as a health-system-affiliated CVC investing across stages in digital health, care delivery, and biotech, with strategic alignment to its parent.

5Northwell Holdings
TypeDirect peer
Description

The venture and investment arm of Northwell Health, New York's largest healthcare system. Comparable as a large integrated health system's venture function deploying capital into healthcare innovation.

TypeDirect peer
Description

The venture arm of Mayo Clinic, one of the most prestigious U.S. academic medical centers. Comparable as an AMC-affiliated investor and licensor focused on translating clinical and research IP into venture-backed companies.

TypeDirect peer
Description

The commercialization and venture arm of Cleveland Clinic, an academic medical center. Comparable as an academic medical system's venture function that commercializes internal innovation and invests in external healthcare startups.

TypeDirect peer
Description

The venture and innovation function of Bon Secours Mercy Health, a large Catholic non-profit health system. Comparable as a non-profit system-affiliated CVC investing in healthcare innovation companies.

TypeDirect peer
Description

A healthcare-focused CVC formed as a joint venture between Cambia Health Solutions and Mosaic Health Solutions. Directly comparable as a payer/provider CVC; co-invested with MGB Ventures in InStride Health's Series C.

TypeEmerging player
Description

The accelerator and venture function of Cedars-Sinai Medical Center, a leading U.S. academic medical center. Comparable as an AMC-affiliated healthcare innovation investor, though with a stronger accelerator-program orientation than MGB Ventures.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries10 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment41 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mass General Brigham Ventures

Healthcare Venture Capitalmassgeneralbrigham.org

Mass General Brigham Ventures is the strategic venture capital arm of Mass General Brigham, investing as a participating investor in early-stage healthcare companies across digital health, AI, and biotech that align with the parent system's clinical and research priorities.

What Mass General Brigham Ventures does

Mass General Brigham Ventures is the strategic venture capital arm of Mass General Brigham Incorporated, a non-profit integrated healthcare system headquartered in Boston, Massachusetts. Founded in 2008 and operating with 11–50 employees from offices in Boston, Cambridge, Salem, and Somerville, the venture unit invests in early-stage healthcare companies whose technologies align with the parent system's clinical and research priorities. Its disclosed portfolio spans pediatric mental health (InStride Health), virtual dementia care (Rippl, subsequently acquired by Harbor Health), AI-powered clinical data abstraction (Carta Healthcare), respiratory therapeutics (Nocion Therapeutics), and preclinical neurodegenerative-disease biotechnology (Violet Therapeutics), with check sizes consistently sized as minority participation rather than lead positions.

The venture unit's investment activity between October 2024 and June 2026 — five rounds across seed, Series A, Series B extension, and Series C totaling over $168 million in combined round size — demonstrates programmatic co-investment alongside ARCH Venture Partners, General Catalyst, GV, F-Prime, UPMC Enterprises, Kin Ventures, and other healthcare-focused funds. The underlying competitive advantage is structural rather than financial: portfolio companies gain potential access to Mass General Brigham's five nationally recognized hospitals, 2.5 million annual patients, nearly $2 billion in annual research funding, and over 3,700 ongoing clinical trials, alongside the parent system's dedicated Artificial Intelligence and Gene and Cell Therapy research institutes.

As a non-profit strategic CVC, Mass General Brigham Ventures is funded by the parent system rather than external LPs, does not disclose revenue or AUM, and participates in rounds as a strategic/clinical-alignment investor. Its business model centers on deal sourcing from the parent system's clinical and research pipeline, portfolio diversification across therapeutic areas and stages, and downstream commercial validation through MGB's integrated care delivery network rather than on management fees or fund performance metrics typical of for-profit VCs.

Mass General Brigham Ventures firmographics

Firmographics
Name
Mass General Brigham Ventures
Legal name
Mass General Brigham Incorporated
Website
https://massgeneralbrigham.org
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
Mass General Brigham Ventures is the strategic venture capital arm of Mass General Brigham, investing as a participating investor in early-stage healthcare companies across digital health, AI, and biotech that align with the parent system's clinical and research priorities.
Ownership category
akta.pro rank

Mass General Brigham Ventures industry classification

Industry
Product category
Healthcare Venture Capital
NAICS
Other Financial Vehicles (52599), Other Investment Pools and Funds (5259)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAHAF
Corporate Strategic Partnership & Ecosystem Investment Arms
SECONDARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
SECONDARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANAAAC
Late-Stage Venture Capital (Series C+)

Keywords

  • Healthcare venture capital
  • Early-stage healthcare investing
  • Biotech venture funding
  • Medical innovation investing
  • Strategic healthcare investments

Where Mass General Brigham Ventures is headquartered

Location

Headquarters

HQ city
Somerville
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Mass General Brigham Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D

Distribution channels3 records

Marketing channels3 records

Mass General Brigham Ventures product offering

Product offering

Core offering

Mass General Brigham Ventures is the venture capital arm of Mass General Brigham, providing strategic equity investments in early-stage healthcare companies. It deploys capital across seed, Series A, Series B, and Series C rounds into startups operating in pediatric mental health, neurodegenerative disease biotechnology, dementia care, clinical data abstraction, and chronic cough therapeutics aligned with the parent system's clinical and research priorities.

Product overview

Mass General Brigham Ventures operates as the venture capital investment arm of Mass General Brigham, an integrated healthcare system. The entity invests in healthcare innovation companies across various stages and therapeutic areas, including pediatric mental health (InStride Health), neurodegenerative disease biotechnology (Violet Therapeutics), dementia care (Rippl), and clinical data management (Carta Healthcare). The investment portfolio spans from seed to Series C funding rounds.

Differentiator

Problem solved

Functional benefit

Brands

  • Mass General Brigham Health Plan: Health insurance plan offered by the Mass General Brigham system
  • Patient Gateway
  • World Medical Innovation Forum
  • MGH Institute of Health Professions
  • Salem Hospital

Products and services

  • Venture Capital Investment Services

Companies that use Mass General Brigham Ventures

Customer profile

Segments3 records

Ideal customer profiles1 record

Mass General Brigham Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Mass General Brigham Ventures partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Dana-Farber Cancer InstitutecoreStrategic or Co-development Partner · 10 March 2026Dana-Farber Cancer Institute and Mass General Brigham agreed to collaborate on physician assistants following what was described as a 'breakup' between the two Boston hospital systems. The physician assistants are employed by Dana-Farber but contracted to work in Brigham's inpatient oncology units, representing a collaborative employment arrangement.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Mass General Brigham Ventures competitors and assessment

Company assessment

Direct peers

  • Amed Ventures: A CVC platform representing a consortium of non-profit health systems investing jointly in healthcare startups. Highly comparable as a multi-system healthcare CVC with overlapping strategic thesis and similar fund mechanics.
  • UPMC Enterprises: The venture and innovation arm of UPMC, a large integrated payer-provider system. Directly comparable as a hospital-system CVC; notably co-invested with Mass General Brigham Ventures in Carta Healthcare's Series B1, evidencing direct overlap in deal-making.
  • Kaiser Permanente Ventures: The venture capital arm of Kaiser Permanente, one of the largest U.S. integrated non-profit healthcare systems. Directly comparable as a health-system-affiliated CVC investing across stages in digital health, care delivery, and biotech, with strategic alignment to its parent.
  • Northwell Holdings: The venture and investment arm of Northwell Health, New York's largest healthcare system. Comparable as a large integrated health system's venture function deploying capital into healthcare innovation.
  • Mayo Clinic Ventures: The venture arm of Mayo Clinic, one of the most prestigious U.S. academic medical centers. Comparable as an AMC-affiliated investor and licensor focused on translating clinical and research IP into venture-backed companies.
  • Cleveland Clinic Innovations: The commercialization and venture arm of Cleveland Clinic, an academic medical center. Comparable as an academic medical system's venture function that commercializes internal innovation and invests in external healthcare startups.
  • Bon Secours Mercy Health Ventures: The venture and innovation function of Bon Secours Mercy Health, a large Catholic non-profit health system. Comparable as a non-profit system-affiliated CVC investing in healthcare innovation companies.
  • Echo Health Ventures: A healthcare-focused CVC formed as a joint venture between Cambia Health Solutions and Mosaic Health Solutions. Directly comparable as a payer/provider CVC; co-invested with MGB Ventures in InStride Health's Series C.

Broad incumbents

  • Optum Ventures: The venture arm of UnitedHealth Group's Optum, the largest healthcare services and innovation platform in the U.S. Comparable as a healthcare-focused CVC, but with substantially larger scale and broader strategic remit than MGB Ventures.

Emerging players

  • Cedars-Sinai Accelerator: The accelerator and venture function of Cedars-Sinai Medical Center, a leading U.S. academic medical center. Comparable as an AMC-affiliated healthcare innovation investor, though with a stronger accelerator-program orientation than MGB Ventures.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

Mass General Brigham Ventures social profiles

Digital presence

Mass General Brigham Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mass General Brigham Ventures leadership team

Management profile

Number of profiles

Mass General Brigham Ventures subsidiaries and ownership

Company hierarchy

Subsidiaries10 records

Mass General Brigham Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mass General Brigham Ventures M&A and investment

M&A and investment

M&A

Investments41 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mass General Brigham Ventures

What does Mass General Brigham Ventures do?

Mass General Brigham Ventures is the venture capital arm of Mass General Brigham, providing strategic equity investments in early-stage healthcare companies. It deploys capital across seed, Series A, Series B, and Series C rounds into startups operating in pediatric mental health, neurodegenerative disease biotechnology, dementia care, clinical data abstraction, and chronic cough therapeutics aligned with the parent system's clinical and research priorities.

Is Mass General Brigham Ventures a public or private company?

Mass General Brigham Ventures is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Mass General Brigham Ventures founded?

Mass General Brigham Ventures was founded in 2008. It employs 11 to 50 people.

Where is Mass General Brigham Ventures based?

Mass General Brigham Ventures is headquartered in Somerville, United States, in the North America region.

Who are Mass General Brigham Ventures's main competitors?

Direct peers on record are Amed Ventures, UPMC Enterprises, Kaiser Permanente Ventures, Northwell Holdings, Mayo Clinic Ventures, Cleveland Clinic Innovations, Bon Secours Mercy Health Ventures and Echo Health Ventures. Optum Ventures is listed as a broad incumbent. Cedars-Sinai Accelerator is listed as an emerging player.

Does Mass General Brigham Ventures have an API?

No public API is recorded for Mass General Brigham Ventures.

What industry is Mass General Brigham Ventures in?

Mass General Brigham Ventures's product category is Healthcare Venture Capital. Its primary akta.pro industry code is FSANAHAF, Corporate Strategic Partnership & Ecosystem Investment Arms, with a secondary code of FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 52599 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinSMEsClaris Biotherapeutics Raises $118M in Series B FundingClaris Biotherapeutics raised $118M in Series B financing led by Samsara Biocapital and Catalio Capital Management. The funds will complete clinical trials for CSB-001 in limbal stem cell deficiency and support a planned 2027 pivotal program. The company also aims to enable pre-commercialization activities.Venture Capital Access OnlineClaris Bio Unveils Development Strategy, Planned Pivotal Study Supported by $118 Million Series B Financing from Top-Tier Investors, and Multiple Leadership AppointmentsClaris Biotherapeutics closed an $118 million Series B financing and appointed Stephen Brady as CEO and Brian Baum as CCO. The funds will support pivotal studies for CSB-001 in limbal stem cell deficiency, planned for 1H 2027, with proof-of-concept results expected in H2 2026.BioSpaceClaris Bio Unveils Development Strategy, Planned Pivotal Study Supported by $118 Million Series B Financing from Top-Tier Investors, and Multiple Leadership AppointmentsClaris Biotherapeutics closed an $118 million Series B financing and appointed Stephen Brady as CEO and Brian Baum as CCO. The funds will support pivotal studies for CSB-001 in limbal stem cell deficiency, planned for 1H 2027, with proof-of-concept results expected in H2 2026.PR NewswireLifespan Vision Ventures Leads Violet Therapeutics' $4.75M Seed Extension FinancingLifespan Vision Ventures led Violet Therapeutics' $4.75 million seed extension financing, with participation from Dementia Discovery Fund, UTEC, Ono Venture Investment, and Mass General Brigham Ventures. The preclinical biotech's lead program targets EphB3, a receptor implicated in microglia-astrocyte signaling, to address synaptic loss in neurodegenerative disease.PR Newswire APACLifespan Vision Ventures Leads Violet Therapeutics' $4.75M Seed Extension FinancingLifespan Vision Ventures led Violet Therapeutics' $4.75 million seed extension financing, with participation from Dementia Discovery Fund, UTEC, Ono Venture Investment, and Mass General Brigham Ventures. The funds will support advancement of Violet's lead small molecule program targeting EphB3 through IND-enabling activities.NewswireLifespan Vision Ventures Leads Violet Therapeutics' $4.75M Seed Extension FinancingLifespan Vision Ventures led Violet Therapeutics' $4.75 million seed extension financing, with participation from Dementia Discovery Fund, UTEC, Ono Venture Investment, and Mass General Brigham Ventures. The funds will support advancement of Violet's lead small molecule program targeting EphB3 through IND-enabling activities.EIN PresswireViolet Therapeutics Raises $4.75M Seed Extension to Advance Novel Therapeutic for Synaptic Preservation and RepairViolet Therapeutics closed a $4.75M seed extension led by Lifespan Vision Ventures. Proceeds will advance its EphB3-targeting small molecule program, which aims to halt cognitive decline via glial-mediated synaptic preservation. The company's CONNECT platform identified EphB3 as a novel target.American City Business JournalsMass General Brigham secures $865M for Ragon buildingMass General Brigham secured $865.5 million in tax-exempt bonds for its two-tower Ragon building, which will house 482 patient beds. The complex, projected to cost nearly $2 billion, is expected to open in two phases between 2027 and 2030. Proceeds will also fund Faulkner Hospital redevelopment and other debt refinancing.SV Health InvestorsViolet Therapeutics raises $10.6 million in seed funding led by the Dementia Discovery Fund (through DDF-2) and co-led by UTEC (University of Tokyo Edge Capital Partners) and Mass General Brigham VentViolet Therapeutics closed a $10.6 million seed round led by the Dementia Discovery Fund (DDF-2) and co-led by UTEC and Mass General Brigham Ventures. The company, founded in 2021, is advancing a lead program targeting neuroinflammation for Alzheimer's disease. The funding marks DDF's first investment from its new fund.GlobeNewswireViolet Therapeutics raises $10.6 million in seed funding led by the Dementia Discovery Fund (through DDF-2) and co-led by UTEC (University of Tokyo Edge Capital Partners) and Mass General Brigham VentViolet Therapeutics closed a $10.6 million seed round led by the Dementia Discovery Fund (DDF-2) and co-led by UTEC and Mass General Brigham Ventures. The company, founded in 2021, is advancing a lead program targeting neuroinflammation for Alzheimer's disease. The funding marks DDF's first investment from its new fund.